/
OKYO
$1.51+$0.01 (+0.33%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$79.0M
52M shares
52-week range
$1.34 – $3.20
9% from low
Exchange
NASDAQ
CS
Change$-2.11
OKYO Pharma Limited Ordinary Shares
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.
www.okyopharma.com- Employees
- 5
- IPO / List date
- May 17, 2022
Held by traders on TradeandTell
No one on the platform currently holds OKYO.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in OKYO as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded OKYO yet.
